| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/15/2004 | US20040010020 Trifluoromethyl-substituted nitrogen compounds; treating type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma |
| 01/15/2004 | US20040010019 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 01/15/2004 | US20040010017 Antithrombotic agents |
| 01/15/2004 | US20040010013 Cannabinoid receptor ligands |
| 01/15/2004 | US20040010011 Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same |
| 01/15/2004 | US20040010010 Melanocortin receptor ligands |
| 01/15/2004 | US20040010009 Excellent inhibitory activity against factor Xa |
| 01/15/2004 | US20040009998 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 01/15/2004 | US20040009997 Treating diseases in which HMG CoA reductase is implicated, such as hyperlipidemia, hypercholesterolemia and atherosclerosis |
| 01/15/2004 | US20040009996 4-(1,2- or 2,1-benzoxazol-5-yl)-2-aminopyrimidines |
| 01/15/2004 | US20040009995 Treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade |
| 01/15/2004 | US20040009991 Calcium channel antagonistic activity; especially useful as analgesics |
| 01/15/2004 | US20040009988 Inhibiting hepatic production of apoprotein B-100 and microsomal triglyceride transfer protein to decrease VLDL and chylomicrons production |
| 01/15/2004 | US20040009984 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure |
| 01/15/2004 | US20040009983 Azaindoles |
| 01/15/2004 | US20040009981 Oxazole, thiazole, 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives of pyrimidines, 1,2,4- and 1,3,5-triazines |
| 01/15/2004 | US20040009979 Use of compounds for the elevation of pyruvate dehydrogenase activity |
| 01/15/2004 | US20040009974 Pyrimidylamino- or triazinylamino- substituted pyrazoles or 1,2,3-triazoles |
| 01/15/2004 | US20040009972 Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase |
| 01/15/2004 | US20040009968 Indazole compounds useful as protein kinase inhibitors |
| 01/15/2004 | US20040009965 Treating hyperproliferative disorders |
| 01/15/2004 | US20040009961 Composition and therapies for hyperlipidaemia-associated disorders |
| 01/15/2004 | US20040009914 Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis |
| 01/15/2004 | US20040009905 Templates consist of cyclized peptides containing at least two residues in said cyclized peptide are joined by a naphthyl ring; and having bonded to it a linear peptide |
| 01/15/2004 | US20040009901 Identifying and administering an agent that enhances NADPH oxidase activity; diagnosing an autoimmune condition accompanied by NADPH oxidase deficiency |
| 01/15/2004 | US20040009895 Also stimulating interleukin-18 or GM-CSF by administering lactoferrin |
| 01/15/2004 | US20040009595 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| 01/15/2004 | US20040009248 Method for improving the cell protection |
| 01/15/2004 | US20040009244 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 01/15/2004 | US20040009216 Administering liposomes comprising phospholipids and an aqueous layer, said liposomes having specified average diameter; treating various cardiovascular disorders, reducing cholesterol |
| 01/15/2004 | US20040009167 Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain; use in preventing or treating a pathogen infection in a cell or organism |
| 01/15/2004 | US20040009163 HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |
| 01/15/2004 | US20040009125 First series of intranasal administration of E-selectin over period of two weeks, followed by a booster administration of E-selectin after at least two weeks from the first administration of E-selectin to minimize brain tissue damage |
| 01/15/2004 | DE10229070A1 Phenylderivate 5 Phenyl derivatives 5 |
| 01/15/2004 | CA2498049A1 At<sb>1</sb> receptor antagonists for preventing secondary strokes |
| 01/15/2004 | CA2492010A1 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 01/15/2004 | CA2491848A1 Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
| 01/15/2004 | CA2491789A1 Diphenylazetidinone derivatives for treating disorders of the lipid metabolism |
| 01/15/2004 | CA2491712A1 New drug combinations based on magnesium salts and fibrinolytics |
| 01/15/2004 | CA2491687A1 A robust, inducible cardiac preferred expression system for transgenesis |
| 01/15/2004 | CA2491685A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising 1,2-prolpylene glycol |
| 01/15/2004 | CA2491682A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | CA2491479A1 Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event |
| 01/15/2004 | CA2491478A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | CA2491477A1 Indolin phenylsulfonamide derivatives |
| 01/15/2004 | CA2491464A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives |
| 01/15/2004 | CA2491455A1 Novel use of imidazotriazinones |
| 01/15/2004 | CA2491406A1 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 01/15/2004 | CA2491321A1 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 01/15/2004 | CA2491217A1 New drug combinations based on sodium channel blockers and magnesium salts |
| 01/15/2004 | CA2491132A1 Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors |
| 01/15/2004 | CA2490988A1 Use of cetp inhibitors and antihypertensive agents as well as optionally hmg coa reductase inhibitors |
| 01/15/2004 | CA2490714A1 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | CA2490470A1 Pyrazole urea neuropeptide y y5 receptor antagonists |
| 01/15/2004 | CA2490463A1 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough |
| 01/15/2004 | CA2490097A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| 01/15/2004 | CA2489563A1 Compositions and methods for amelioration of human female sexual dysfunction |
| 01/15/2004 | CA2489402A1 New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 01/15/2004 | CA2489398A1 Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| 01/15/2004 | CA2489251A1 Quinazoline derivatives |
| 01/15/2004 | CA2488736A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents |
| 01/15/2004 | CA2460051A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
| 01/14/2004 | EP1380594A1 Fibroblast growth factor-10 |
| 01/14/2004 | EP1380593A1 Soluble rage protein |
| 01/14/2004 | EP1380562A1 Carboxylic acid derivative and salt thereof |
| 01/14/2004 | EP1380296A1 Hsp inductor |
| 01/14/2004 | EP1380290A1 Cross-beta structure pathway and its therapeutic relevance |
| 01/14/2004 | EP1379869A1 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal |
| 01/14/2004 | EP1379695A2 New polynucleotides and polypeptides of the ifnalpha-21 gene |
| 01/14/2004 | EP1379694A2 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |
| 01/14/2004 | EP1379688A2 Polymorphisms in the human cmoat gene and uses thereof |
| 01/14/2004 | EP1379679A2 Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof |
| 01/14/2004 | EP1379672A2 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc) |
| 01/14/2004 | EP1379662A2 Sulfatases and methods of use thereof |
| 01/14/2004 | EP1379656A2 G-protein coupled receptor molecules and uses thereof |
| 01/14/2004 | EP1379652A2 Human nucleic acid molecules and polypeptides encoding a human ion channel expressed in spinal cord and brain |
| 01/14/2004 | EP1379648A1 Full-length human cdnas encoding potentially secreted proteins |
| 01/14/2004 | EP1379630A2 Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| 01/14/2004 | EP1379628A2 Kinases and phosphatases sequences, and use thereof |
| 01/14/2004 | EP1379557A2 Use of cd25 binding molecules in steroid-resistant patients |
| 01/14/2004 | EP1379550A2 A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences |
| 01/14/2004 | EP1379533A2 Novel cyclo azaphospha hydrocarbons |
| 01/14/2004 | EP1379528A1 Pyrazolopyrimidines as therapeutic agents |
| 01/14/2004 | EP1379524A2 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 01/14/2004 | EP1379523A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 01/14/2004 | EP1379519A1 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379517A2 Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 01/14/2004 | EP1379516A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 01/14/2004 | EP1379515A1 Lipid lowering biphenylcarboxamides |
| 01/14/2004 | EP1379507A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS |
| 01/14/2004 | EP1379504A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors |
| 01/14/2004 | EP1379503A1 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379502A1 Nicotinic acetylcholine receptor ligands |
| 01/14/2004 | EP1379495A2 Ligands of the alpha-v-beta 6 integrin |
| 01/14/2004 | EP1379494A1 Fused bicyclic or tricyclic amino acids |
| 01/14/2004 | EP1379279A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine |
| 01/14/2004 | EP1379276A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/14/2004 | EP1379266A2 Modified annexin proteins and methods for preventing thrombosis |
| 01/14/2004 | EP1379265A2 Short bioactive peptides and methods for their use |
| 01/14/2004 | EP1379262A1 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles |